MOVENTIG® named “Most Innovative Product” 2020

Constipation, stomach pains, and nausea affect patients with opioid-induced constipation (OIC) to such an extent that they can be forced to discontinue treatment. Conventional laxatives are often insufficient. The new PAMORA drug class can help target the adverse intestinal effects of opioids – without negatively affecting central pain inhibition. Naloxegol (MOVENTIG®) is the first of … [Read more…]